Please ensure Javascript is enabled for purposes of website accessibility

What's Behind Intrexon's Steep Sell-Off Today

By Todd Campbell - Apr 21, 2016 at 4:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A bearish research report is weighing on shares.


What: After Spotlight Research issued a negative report questioning the company's business model, shares of Intrexon Corp.(PGEN 0.00%) crashed 26.4% today.

So what: In a report released earlier today, Spotlight Research (formerly Forensic Research Analyst) questioned whether or not Intrexon Corp.'s business plans justify its multi-billion dollar market cap. Specifically, concerns were raised surrounding Intrexon's Oxitec subsidiary, which is developing male mosquitoes that can't reproduce viable mosquitoes.

These genetically modified mosquitoes have been touted as a potential solution to limiting the spread of the Zika virus. However, Oxitec's technology has been around for years, and despite the potential to use it to control other significant mosquito-transmitted disease, including Dengue fever, this approach has not become widely adopted.

Now what: Oxitec was acquired by Intrexon in 2015 for $160 million, and speculation surrounding the use of its mosquitoes to control the Zika virus is a major reason why Intrexon's shares jumped about 20% year to date through yesterday.

Despite several potentially promising research programs underway, Intrexon remains unprofitable, with management reporting an operating loss of $147 million in 2015. After adjusting that figure for other non-operating line items, Intrexon lost investors $84 million last year.

Investing in companies that are highly speculative carries a fair amount of risk, and often, that risk can lead to nausea-inspiring pops and drops. While Intrexon may be intriguing, the jury is still out on Oxitec's ability to curb the spread of Zika virus better than existing methods.

For that reason, investors might be better off focusing on other investment ideas rather than bargain hunting this stock. Eventually, Intrexon will either demonstrate that its approach is effective, or it won't. Until then, expect this company's shares to remain highly volatile.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Precigen, Inc. Stock Quote
Precigen, Inc.
$1.25 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.